Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.
This search will output a list of trials for which you may be eligible based on the criteria you enter.
For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.
|NCT02873962||II||Partially platinum sensitive or resistant ovarian cancer (for combo w/ rucaparib patients have to be BRCA WT and have no prior PARP inhibitor)||A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer||MA||View Drugs||View Results |
|Bevacizumab||immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin||VEGF antagonist||Approved in Ovarian Cancer|
|Nivolumab||BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo||Blocks PD-L1/2 inhibition of T cells||Approved in Other Cancers|
|Rucaparib||Rubraca, CO-338, PF 01367338, AG-014699||PARP inhibitor||Approved in Ovarian Cancer|
|NCT02484404||I/II||Recurrent ovarian cancer||Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers||MD||View Drugs||View Results |
|Cediranib||Recentin, Cediranib maleate, AZD2171||VEGFR1-3 kinase inhibitor|
|Durvalumab||Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi||Blocks PD-L1 inhibition of T cells||Approved in Other Cancers|
|Olaparib||AZD2281, Lynparza||PARP inhibitor||Approved in Ovarian Cancer|